Summary of AVITA Medical, Inc. Q2 2026 Earnings Call

1Key Financial Results and Metrics

Revenue: Achieved $21.7 million, an 18% increase year-over-year and a 13% sequential growth, marking the first quarter surpassing $20 million.

Gross Margin: Improved to 81.9%, up from 81.2% in the prior year, supported by strong RECELL performance.

Operating Expenses: Held steady at $24.6 million, a 6% reduction compared to Q2 2025, indicating improved operational efficiency.

Net Loss: Reduced to $7.7 million from $9.9 million year-over-year, with an operating loss of $6.9 million.

Cash Position: Ended the quarter with $11.1 million in cash and equivalents, with net cash use improving to approximately $3.2 million.

2Strategic Updates and Business Highlights

Product Performance:

RECELL: Generated $8.5 million in revenue, growing 13% sequentially. Notable adoption of RECELL GO Mini for smaller wounds.

Cohealyx: Revenue of $1.7 million, showing 16% sequential growth, with a healthy pipeline of 55 active Value Analysis Committee (VAC) reviews.

PermeaDerm: Generated $600,000 in revenue, with early-stage commercial adoption as a wound temporizer.

Market Expansion: Continued growth in international markets, particularly with RECELL, which saw a 26% sequential revenue increase.

Reimbursement Changes: Transitioning to new Category I CPT codes for skin cell suspension autograft expected to simplify reimbursement processes and enhance predictability for providers.

3Forward Guidance and Outlook

Revenue Guidance: Raised for the full year 2026 to a range of $86 million to $89 million, reflecting a growth of 20% to 24% over 2025.

Cash Flow: Introduced guidance to achieve cash flow breakeven and begin generating cash in Q4 2026, supported by scaling revenue and disciplined expense management.

4Bad News, Challenges, or Points of Concern

Adoption Rates: While RECELL utilization is growing, the overall adoption of Cohealyx and PermeaDerm remains in early stages, indicating potential challenges in market penetration.

Reimbursement Transition Risks: Concerns about a transitional air pocket as providers adapt from the old to new coding structures, which may temporarily disrupt adoption.

Competitive Pressures: The need to demonstrate the economic benefits of AVITA’s products against competitors remains critical as the market evolves.

5Notable Q&A Insights

Guidance Increase: Management attributed the guidance increase to a stronger growth trajectory driven by RECELL GO Mini and improved reimbursement stability.

Reimbursement Structure: The previous complex reimbursement structure caused confusion and delays in adoption; the new simplified codes are expected to alleviate this issue.

Sales Feedback: Sales reps report strong clinical effectiveness and economic benefits of all three products, with ongoing efforts to maximize synergies among them.

Gross Margin Management: The company is focused on operational efficiencies and pricing strategies to maintain and potentially improve gross margins as product mix evolves. Overall, AVITA Medical demonstrated solid financial performance and strategic progress in Q2 2026, while also navigating challenges related to market adoption and reimbursement transitions.